|
Study shows injured kidneys can be used for transplants - NephrologyNews.com |
 |
 |
|
A new study led by researchers at Yale finds that kidneys from deceased donors who had acute injuries may be more viable than previously thought, and should be considered to meet the growing demand for organ transplants.
Donated kidneys with acute injury are often discarded for fear of poor outcomes such as delayed function and even premature kidney transplant failure. Given the growing need for transplant organs, the researchers embarked on the largest multicenter observational study of its kind to date, including more than 1,600 deceased donors. They examined associations between acute kidney injury in donors, rates of kidney discard, and recipient kidney function in the short term as well as six months after transplantation.
As anticipated, the researchers found an association between AKI and organ discard. They also found that injured kidneys were associated with "delayed graft function (DGF)," or the need for continued dialysis support in the first week after transplantation. But unexpectedly, the study did not find a link between deceased-donor kidney injury and poor kidney transplant function six months later.
"What we saw was, with worsening AKI in the donor, the six-month outcome was actually better for recipients who experienced DGF," said Isaac E. Hall, M.D., investigator in the Program of Applied Translational Research at Yale School of Medicine and first author of the study.
Six-month transplant function was worst for those with delayed graft function who had received a donated kidney with no apparent injury.
Hall suggested that organs acutely injured in the donor might develop "ischemic preconditioning," a mechanism that could protect the organs from the effects of subsequent injury. Another possible explanation is that the successfully transplanted kidneys with AKI were of otherwise higher quality than the rejected kidneys with AKI, though the study did adjust for many important variables like donor age and comorbidity.
"There appears to be room to attempt more transplants using these AKI kidneys rather than throwing them away," said Chirag R. Parikh, M.D., director of the Program of Applied Translational Research and senior author of the study. "Even if it only means a few dozen more kidney transplants each year, those are patients who would come off of the waiting list for transplants sooner and have much better survival than continuing on dialysis in hopes of seemingly higher-quality kidney offers, which may never come in time," he said.
The study was published March 11 in the American Journal of Transplantation.
Other authors include Bernd Shröppel, Mona D. Doshi, Joseph Ficek, Francis L. Weng, Rick D. Hasz, Heather Thiessen-Philbrook, and Peter P. Reese.
|
|
NxStage to Present Abstract on Home Nocturnal Therapy with System One at ... - CNNMoney |
|
|
|
LAWRENCE, Mass., March 16, 2015 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of dialysis products, today announced a late breaking abstract, "Home Nocturnal Hemodialysis with Low Dialysate Volume: A Cross-Over Study," outlining favorable outcomes for more frequent home hemodialysis patients who transitioned to home nocturnal hemodialysis with the NxStage® System One?. The National Kidney Foundation accepted the abstract for poster presentation during its 2015 Spring Clinical Meeting in Dallas, Texas.
Results from this study, conducted by nephrologists Brigitte Schiller, M.D. and Brent W. Miller, M.D., supported the Food and Drug Administration's (FDA) recent clearance of the NxStage System One to perform therapy overnight while patients are at home sleeping, known commonly as nocturnal therapy. The Company's System One is the first and only hemodialysis machine cleared by the FDA for this indication.
"This study demonstrates that at-home, overnight hemodialysis is both safe and effective for ESRD patients, and can help them live a full life," said Brigitte Schiller, M.D., Chief Medical Officer of Satellite Healthcare and Principal Investigator of NxStage's home nocturnal hemodialysis trial. "Now that the FDA has cleared the NxStage System One for nocturnal therapy, I am even more committed to furthering the conversation on nocturnal therapy and the incredible benefits it can offer to our patients' health and quality of life."
This poster presentation will take place on Thursday, March 26, 2015 from 6:00 -7:30pm at the Gaylord Texan, and will remain on display through Saturday, March 28, 2015.
Despite the health benefits that home hemodialysis may provide to those with chronic kidney disease, this form of therapy is not for everyone. The reported benefits of home hemodialysis may not be experienced by all patients. The risks associated with hemodialysis treatments in any environment include, but are not limited to, high blood pressure, fluid overload, low blood pressure, heart-related issues, and vascular access complications. The medical devices used in hemodialysis therapies may add additional risks including air entering the bloodstream and blood loss due to clotting or accidental disconnection of the blood tubing set. Certain risks are unique to the home. Treatments at home are done without the presence of medical personnel and on-site technical support. Patients and their partners must be trained on what to do and how to get medical or technical help if needed.
Additional Risks Associated with Nocturnal Home Hemodialysis Therapy
The NxStage System One may be used at night while the patient and care partner are sleeping. Certain risks associated with hemodialysis treatment are increased when performing nocturnal therapy due to the length of treatment time and because therapy is performed while the patient and care partner are sleeping. These risks include, but are not limited to, blood access disconnects and blood loss during sleep, blood clotting due to slower blood flow or increased treatment time or both, and delayed response to alarms when waking from sleep. Ancillary anticoagulant infusion pumps and fluid leak detection devices may be used to decrease certain risks for home hemodialysis treatments performed at any time, but NxStage requires the use of fluid leak detectors to identify leaks from the vascular access, Cycler and Cartridge when performing nocturnal therapy with the NxStage System One.
About the NxStage System One
The NxStage System One is the first and only truly portable hemodialysis system cleared specifically by the FDA for home hemodialysis and home nocturnal hemodialysis. Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy. When combined with the NxStage PureFlow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on demand. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, including while they are sleeping - at home or on vacation and at a medically appropriate treatment frequency. http://www.nxstage.com/.
About NxStage Medical
NxStage Medical Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the Company's website at www.nxstage.com.
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2014. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Media contact:
Kristen K. Sheppard, Esq.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Tel: (978) 332-5923
Logo - http://photos.prnewswire.com/prnh/20110503/MM94799LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nxstage-to-present-abstract-on-home-nocturnal-therapy-with-system-one-at-nkf-2015-spring-clinical-meeting-300050665.html
SOURCE NxStage Medical Inc.
|
|
|
New hope for kidney disease - ScienceBlog.com (blog) |
|
|
|
Researchers have made a discovery that could see patients with kidney disease no longer having to resort to dialysis or kidney transplants.
Chronic kidney disease (CKD) can be caused by a number of factors, and results in permanent, irreversible scarring of the kidney leading to end-stage renal disease (ESRD). Once a patient has reached this point their only option is dialysis or transplantation.
Research led by Monash University scientists has shown for the first time the effectiveness of combining a stem cell-based therapy with an anti-scarring agent to reverse scarring and markers of kidney injury, reducing the need for dialysis or transplantation.
Associate Professor Sharon Ricardo, Department of Anatomy and Developmental Biology, said the researchers had discovered that adult stem cells, combined with a protein called serelaxin, could reverse scarring.
“Adult stem cells have proved promising for the treatment of a wide range of diseases, including kidney disease,” she said.
“We decided to investigate how adult stem cells could help reduce the scarring effect. We demonstrated that adult stem cells and serelaxin on their own have a limited effect on reversing kidney scarring, yet when used in combination with serelaxin can provide significant protection from kidney damage.”
Associate Professor Ricardo said the adult cells did not turn into kidney cells, rather they help the injured kidney repair itself.
“However, the potential of these stem cells is reduced in patients who have a lot of scarring due to the disease.”
Associate Professor Chrishan Samuel, Department of Pharmacology, said serelaxin was currently undergoing phase III clinical trials to assess its ability to treat symptoms and end-stage mortality in patients with acute heart failure.
“We believe that by reducing the scarring associated with chronic kidney disease, serelaxin creates an improved environment for the administration of stem cells, and can directly improve the viability and therapeutic efficacy of introduced stem cells,” he said.
PhD candidate Brooke Huuskes, Department of Anatomy and Developmental Biology, said the finding was important as kidney disease was increasing worldwide placing huge economic burden on health care systems.
“There is no cure for kidney disease, and alarmingly three out of four people on dialysis will die waiting for a kidney transplant, and even those who are lucky enough to receive a transplant often end up back on dialysis due to rejection or graft failure,” she said.
Brooke, who had a kidney transplant in 2010, said it meant a lot to her to be able to do research into something that was very personal to her and that she was passionate about.
The research was published in The Journal of the Federation of American Societies for Experimental Biology.
|
|
Therapy reduces chances of dialysis - Zee News |
|
|
|
Melbourne: A new stem cell therapy discovered by Australian researchers could help patients with chronic kidney disease to avoid dialysis or kidney transplants.
A research led by scientists of the Monash University has for the first time shown the effectiveness of combining a stem cell-based therapy with an anti-scarring agent which would reverse scarring and markers of kidney injury, thereby reducing the need for dialysis or transplantation.
The researchers discovered that adult stem cells when combined with a protein called serelaxin, could reverse scarring.
"Adult stem cells have proved promising for the treatment of a wide range of diseases, including kidney disease.
"We decided to investigate how adult stem cells could help reduce the scarring effect. We demonstrated that adult stem cells and serelaxin on their own have a limited effect on reversing kidney scarring, yet when used in combination with serelaxin can provide significant protection from kidney damage, said Sharon Ricardo from the Department of Anatomy and Development Biology."
Ricardo said the adult cells did not turn into kidney cells, rather they help the injured kidney repair itself.
"However, the potential of these stem cells is reduced in patients who have a lot of scarring due to the disease."
According to Chrishan Samuel, from the Department of Pharmacology, serelaxin is currently undergoing phase III clinical trials to assess its ability to treat symptoms and end-stage mortality in patients with acute heart failure.
Chronic kidney disease (CKD) can be caused by a number of factors, and results in permanent, irreversible scarring of the kidney leading to end-stage renal disease (ESRD).
Once a patient has reached this point their only option is dialysis or transplantation.
According to Brooke Huuskes, Department of Anatomy and Developmental Biology, the finding was important as kidney disease were at a rise worldwide placing huge economic burden on health care systems.
|
|
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
